Skip to Content

Tranexamic acid Disease Interactions

There are 5 disease interactions with tranexamic acid:

Major

Tranexamic acid (applies to tranexamic acid) intravascular clotting

Major Potential Hazard, Moderate plausibility. Applicable conditions: Disseminated Intravascular Coagulation

The use of tranexamic acid is contraindicated in patients with active intravascular clotting.

Major

Tranexamic acid (applies to tranexamic acid) subarachnoid hemorrhage

Major Potential Hazard, High plausibility. Applicable conditions: Intracranial Hemorrhage

The use of tranexamic acid is contraindicated in patients with subarachnoid hemorrhage. Cerebral edema and infarction can occur in patients with subarachnoid hemorrhage.

References

  1. "Product Information. Cyklokapron (tranexamic acid)." Pharmacia and Upjohn, Kalamazoo, MI.
Moderate

Tranexamic acid (applies to tranexamic acid) color vision defect

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Visual Defect/Disturbance

Tranexamic acid should be used with caution in patients with acquired defective color vision or visual disturbances. Poorly characterized visual abnormalities have been reported in patients during tranexamic acid therapy. Retinal degeneration in a variety of animal species (not human) at oral and IV doses 3 to 40 times the recommended human dosage has been noted. Ophthalmologic testing and monitoring (visual acuity, and optical coherence tomography) prior to and at regular intervals during treatment is recommended for patients treated longer than 3 months. Discontinue treatment if changes in ophthalmological examination occur.

References

  1. "Product Information. Cyklokapron (tranexamic acid)." Pharmacia and Upjohn, Kalamazoo, MI.
Moderate

Tranexamic acid (applies to tranexamic acid) convulsions

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Seizures

Convulsions have been reported in association with tranexamic acid treatment, particularly in patients receiving tranexamic acid during cardiovascular surgery and in patients inadvertently given tranexamic acid into the neuraxial system. Caution is advised if administering in patients with convulsive disorders.

Moderate

Tranexamic acid (applies to tranexamic acid) renal dysfunction

Moderate Potential Hazard, High plausibility.

Tranexamic acid is primarily eliminated by the kidney. Approximately 95% of tranexamic acid is excreted in the urine unchanged. The serum concentration of tranexamic acid is increased and the elimination half-life prolonged in patients with renal impairment. Therapy with tranexamic acid should be administered cautiously and dosages reduced in patients with compromised renal function. Clinical monitoring of renal and clotting functions is recommended.

References

  1. "Product Information. Cyklokapron (tranexamic acid)." Pharmacia and Upjohn, Kalamazoo, MI.

Tranexamic acid drug interactions

There are 36 drug interactions with tranexamic acid

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.